Michael S Perry insider trades: Arrowhead Pharmaceuticals (ARWR) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
and 1 more company
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | ARWR | ↓ Sell | 11,600 | $87.30 | $1.0M | Direct | Aug 20, 2026 (2d) |
| Dec 5, 2025 | ARWR | ↓ Sell | 16,250 | $61.03 | $992K | Direct | Dec 9, 2025 (4d) |
| Nov 21, 2022 | RCEL | ↓ Sell | 150,000 | $7.18 | $1.1M | Direct | Nov 22, 2022 (1d) |
| Feb 24, 2022 | RCEL | ↓ Sell | 10,812 | $8.74 | $94K | Direct | Feb 25, 2022 (1d) |
| Jan 3, 2022 | ARWR | ↓ Sell10b5-1 | 4,500 | $64.71 | $291K | Direct | Jan 4, 2022 (1d) |
| Sep 1, 2021 | RCEL | ↓ Sell | 11,220 | $20.68 | $232K | Direct | Sep 7, 2021 (6d) |
| Jun 2, 2021 | RCEL | ↓ Sell | 23,000 | $17.33 | $399K | Direct | Jun 4, 2021 (2d) |
| Jan 4, 2021 | ARWR | ↓ Sell | 4,000 | $76.09 | $304K | Direct | Jan 5, 2021 (1d) |
| Sep 16, 2020 | RCEL | ↓ Sell | 47,861 | $27.19 | $1.3M | Direct | Sep 16, 2020 (0d) |
| Sep 11, 2020 | RCEL | ↓ Sell | 27,128 | $26.08 | $708K | Direct | Sep 11, 2020 (0d) |
| May 12, 2020 | ARWR | ↓ Sell | 36,000 | $35.83 | $1.3M | Direct | May 13, 2020 (1d) |
| Sep 11, 2019 | ARWR | ↓ Sell | 185,000 | $29.41 | $5.4M | Direct | Sep 11, 2019 (0d) |
| Mar 22, 2018 | APHB | ↑ Buy | 181,820 | $1.10 | $200K | Indirect | Mar 26, 2018 (4d) |
| Mar 27, 2012 | PARD | ↓ Sell | 1,599 | $0.83 | $1K | Direct | Mar 27, 2012 (0d) |
| Feb 16, 2012 | PARD | ↓ Sell | 6,346 | $0.87 | $6K | Direct | Feb 17, 2012 (1d) |
| Apr 13, 2011 | PARD | ↓ Sell | 45,140 | $0.37 | $17K | Direct | Apr 14, 2011 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ARWR insiders
Open-market trades in the last 12 months
About Michael S Perry's insider trades
Michael S Perry is a director at Arrowhead Pharmaceuticals (ARWR). Since Apr 13, 2011, Michael has reported 1 open-market purchase worth $200K and 15 sales worth $13.2M on SEC Form 4. In the last 12 months: 2 sales ($2.0M).
1 sale (2% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (38 filings), option exercises (5 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARWR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.